May 15 Mylan Inc said a U.S. district
court dismissed a case by Israeli drugmaker Teva Pharmaceutical
Industries Ltd intended to block the U.S. health
regulator from approving generic versions of Teva's multiple
sclerosis drug Copaxone.
U.S. generic drugmaker Mylan said it had intervened in the
lawsuit in support of the U.S. Food and Drug Administration.
"Following the court's decision against Teva, we continue to
see no barrier to FDA approval of Mylan's generic Copaxone
following patent expiry," Mylan CEO Heather Bresch said in a
(Reporting by Esha Dey in Bangalore; Editing by Savio D'Souza)